Journal of Clinical and Experimental Hematopathology · 2020 · 10 citations · 18 references
MedicineImmunologyOncologyCancer ImmunologyImmunotherapyTumor ImmunologyAntitumor T Cell ResponsesCancer ImmunotherapyCytotoxic T Lymphocyte ResponsesImmune Checkpoint RegulationLymphoid TissueTumor-infiltrating LymphocytesPd-1 SignalingPd-l1 BlockadeProgrammed Cell Death Ligand 1 RegulationProgrammed Cell Death Protein 1 (Pd-1) PathwayProgrammed Death-1 InhibitionProgrammed Death-ligand 1 BiomarkerProgrammed Death-ligand 1 InhibitionRegional Lymph Node Involvement
18
Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
Leena Gandhi, Delvys Rodríguez‐Abreu, Shirish M. Gadgeel et al. · New England Journal of Medicine · 2018 · 6.6K citations · Full text
Medicine, Oncology, Pharmacology +16
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Robert L. Ferris, George R. Blumenschein, Jérôme Fayette et al. · New England Journal of Medicine · 2016 · 5.1K citations · Full text
Medicine, Oncology, Metastasis +5
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
Peter Schmid, Sylvia Adams, Hope S. Rugo et al. · New England Journal of Medicine · 2018 · 4.4K citations · Full text
Medicine, Oncology, Pharmacology +17
Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity
Tyler J. Curiel, Shuang Wei, Haidong Dong et al. · Nature Medicine · 2003 · 1.3K citations
Life Sciences, Immunology, Oncology +15
Expression of Programmed Death 1 Ligands by Murine T Cells and APC
Tomohide Yamazaki, Hisaya Akiba, Hideyuki Iwai et al. · The Journal of Immunology · 2002 · 946 citations · Full text